Wellington Management
VC Fund
Boston, United States
Wellington Management is a VC fund in Boston focused on Biotechnology and Health Care. Wellington Management focuses on investment management. The company applies its full resources to meet the needs of the institutional clients they serve. Their investment approaches span equity, fixed income, currency, commodity, and alternative markets. They also offer asset allocation, multi-manager, and speciality approaches.
- Total investments:
- 348
- Last investment:
- Lead investor:
- 34%
- Fund size:
- $15M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Wellington Management invests in
Stages Wellington Management invests in
Countries Wellington Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 13 contacts → | |||
Investment Focus
Industry
- Biotechnology 93 (27%)
- Health Care 75 (22%)
- Medical 51 (15%)
- Software 42 (12%)
- Therapeutics 38 (11%)
Stage
- Series C 60 (17%)
- Series B 53 (15%)
- Series D 40 (11%)
- Post-IPO Equity 38 (11%)
- Series E 35 (10%)
Country
- United States 224 (64%)
- United Kingdom 12 (3%)
- India 8 (2%)
- Germany 5 (1%)
- China 4 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alain Mandy
Managing Director & Chief Operating Officer Funds
|
Managing Director & Chief Operating Officer Funds | Total investments: 2 | Find email | |
Jean Hynes
CEO, Managing Partner, and Portfolio Manager
|
CEO, Managing Partner, and Portfolio Manager | Total investments: 0 | Find email | |
Jackson Cummings
Head of Diverse Founders Investing
|
Head of Diverse Founders Investing | Total investments: 4 | Find email | |
Joshua Sommerfeld
Private Equity Principal
|
Private Equity Principal | Total investments: 2 | Find email | |
Matthew Witheiler
Private Equity
|
Private Equity | Total investments: 13 | Find email | |
| See all 13 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Research Lab. Exploring new frontiers of voice generation. We are researching and deploying novel methods in voice AI to make content enjoyable in any language and voice to benefit new audiences and viewers. Our mission is to make content universally accessible in any language & voice. | $300M / Secondary Market / Sep 29, 2026 | ||
| Nscale is an AI GPU cloud platform that provides scale computing to the generative AI market. It develops AI-ready data centers, deploys GPU infrastructure, and delivers AI cloud services. Its AI private cloud platform supports the entire generative AI lifecycle, enabling developers to run and train AI models. It also provides bare metal andvirtualized GPU nodes, Kubernetes-native services (NKS), AI workload scheduling empowered by SLURM, and advanced serverless and dedicated inferencing options. | $3.4B / Convertible Note / Sep 25, 2026 | ||
| Temporal Technologies is a computer software company that enables its users to build and operate resilient applications using developer-friendly primitives. It specializes in the fields of information technology, software development, and computer software. It was founded in 2019 and headquartered in Bellevue, Washington. | $550M / Series E / Sep 14, 2026 | ||
| tabby provides consumers across the GCC with the flexibility to pay for their online and in-store purchases in interest-free installments. tabby helps over 2,000 leading retailers grow their sales. | $233M / Series F / Sep 14, 2026 | ||
| Clay provides a platform for go-to-market teams to use unique data and AI. The platform offers access to over 100 data providers for contact information, firmographics, and other data points. It also includes an AI research agent to automate manual research and create flexible workflows. | $115M / Series D / Sep 09, 2026 | ||
| Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications. | $380M / Post-IPO Equity / Sep 08, 2026 | ||
| Muon Space is an end-to-end space systems company that designs, builds, and operates mission-optimized satellite constellations to deliver critical data and enable real-time compute and decision-making in space. Its proprietary technology stack, Halo™, integrates advanced spacecraft platforms, robust payload integration and management, and apowerful software-defined orchestration layer to enable high-performance capabilities at unprecedented speed – from concept to orbit. With state-of-the-art production facilities in Silicon Valley and a growing track record of commercial and national security customers, Muon Space is redefining how critical Earth intelligence is delivered from space. | $250M / Series C / Aug 20, 2026 | ||
| Avere Therapeutics is a biotechnology company that develops oral interleukin-23 receptor antagonist therapies for chronic inflammatory diseases. The company is advancing AVR-001, an oral, once-weekly IL-23 receptor antagonist designed to modulate IL-23 signaling. Its work focuses on leveraging a validated immunology target with clinical proof ofconcept across conditions such as psoriasis, ulcerative colitis, Crohn’s disease, and psoriatic arthritis. Avere Therapeutics concentrates on achieving convenient dosing while maintaining efficacy through higher and more consistent drug exposure and a longer half-life. Its programs are intended to offer pill-based treatment options for patients who currently rely on injectable IL-23 inhibitors. | $500M / Private Equity / Aug 10, 2026 | ||
| Whatnot is a Los Angeles-based startup that creates a place where avid collectors could come together over shared interests. Whatnot is a marketplace to buy and sell authentic collectible items. Whatnot was founded in 2019, in California. | $547M / Series G / Aug 06, 2026 | ||
| Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases acrosstherapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis. | $125M / Post-IPO Equity / Aug 06, 2026 | ||
| See all 348 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Wellington Management invest in?
Wellington Management invests primarily in Biotechnology, Health Care and Medical startups, most often at Series C and Series B stage. Most of the 348 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Wellington Management?
Public channels for Wellington Management include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Wellington Management?
The team at Wellington Management includes Alain Mandy (Managing Director & Chief Operating Officer Funds), Jean Hynes (CEO, Managing Partner, and Portfolio Manager) and Jackson Cummings (Head of Diverse Founders Investing), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
